July 14, 2015 – ROCHESTER, NY – The latest iteration of Clinical Conductor CTMS continues the proven strategy of providing research organizations with the most in-depth features and functionality available, further distancing the application from others in the industry, which fail to provide the tools necessary for truly complete clinical research management.
Adopting scientific quality measurement that recognizes that clinical trials are a service will reap benefits.
EDC has become the data management platform of choice around the world, offering advantages such as increasing the quality and timely collection of data. Medrio, an EDC company that offers eClinical software solutions, has quoted that 70% of clinical trials are using EDC as a forms of collecting data in the United States. In China, we have seen adoption rates for EDC increase dramatically in recent years, fuelled by improved technology developments in mobile applications, and the increasing experience with EDC usage in clinical research.
Considerable quality investments over the past decade have had little demonstrable impact on clinical trial performance and quality.
The use of small animal models in basic and preclinical research is now an integral part of developing and testing new drugs.
It is well known within the industry that being on a sponsor’s preferred provider list affords a critical leg up to providers hoping to win business. Phase II/III work is no exception. In the 7th edition of Industry Standard Research’s CRO Quality Benchmarking - Phase II/III Service Providers report, ISR digs a bit deeper into the dynamics of preferred provider lists and how these lists affect CRO selection for Phase II/III studies.
An independent judging panel will select three finalists from the submissions.
OmniComm Systems, a global provider of clinical data management technology and services, announced that it has signed a reselling partnership agreement with Tri-I Biotech Shanghai Inc.
Synexus has announced plans to open three new research centers in Bulgaria, Poland and Romania.
Almac Group announced the successful completion of the Health Sciences Authority (HSA) inspection of its new Asia Pacific headquarters in Singapore.
The budget increase for NIH brought strong support from the biomedical research community and medical societies across the board.
New faces among the Pharma Industry rise the ranks
Parexel announced expanded services and capabilities in model-based drug development (MBDD) through its Quantitative Clinical Development (QCD) group.
Certara®, a global biosimulation technology-enabled drug development company, announced the merger of its consulting group, Pharsight Consulting Services.
A case study by Pfizer & The Avoca Group on the development of an overarching strategy for Pfizer’s clinical trial quality metrics.
In response to increasing demand of Sharp Clinical Services.
goBalto, Inc., a provider of cloud-based clinical study startup solutions, announced its latest version of goBalto Activate.
Navitas, a regulatory service provider, announced that it has opened a new Latin America hub in Bogota, Colombia. Navitas' expansion into Latin America offers bilingual resources (Spanish and English) and provides document, report and submission level publishing for simple and complex submission applicatioms.